| Document |
Document Title |
|
WO/2003/057164A2 |
Lipids and compositions of lipids that can be used as lipid aggregates (i.e., liposomes) for the delivery of macromolecules and other compounds into cells are provided. The lipids have a general structure represented by formula (I). The ...
|
|
WO/2003/055474A1 |
1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other distu...
|
|
WO/2003/053994A1 |
A compound having formula (I), wherein the O-(CH2)n-N(R1,R2) substituent on the phenyl ring can be in meta or para position; n is 2-4, Re and 'Re are OH, optionally independently etherified or esterified; R1 and R2 are independently (1C-...
|
|
WO/2003/051936A1 |
The present invention provides a catalyst precursor compound and catalyst composition form making polyolefins, an embodiment of the precursor is selected from the following structures: wherein T is a bridging group; M is selected from Gr...
|
|
WO/2003/049666A2 |
The present invention relates to the field of perfumery. More particularly, it concerns compounds comprising at least one $g(b)-oxy or $g(b)-thio carbonyl moiety capable of liberating a perfuming molecule such as, for example, an $g(a),$...
|
|
WO/2003/050073A1 |
Disclosed are compounds of the formula (I) and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, RN, and RC are defined herein. These compounds interact with and inhibit the activity of th...
|
|
WO/2003/050074A1 |
The present invention discloses process for the preparation of (∓)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)-ethyl] cyclohexanol hydrochloride (Venlafaxine hydrochloride) and its novel crystalline polymorphs designated as Form -I, Form ...
|
|
WO/2003/050075A1 |
This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.
|
|
WO/2003/050076A1 |
This invention relates to novel crystalline polymorphic form of venlafaxine hydrochloride which exists in hydrated form (e.g., as a monohydrate), methods for the preparation thereof, and its use.
|
|
WO/2003/048117A2 |
The invention concerns compounds of formula (I), wherein A is a group of formula (a) or (b), wherein: R represents a hydrogen or halogen atom, a -S(O)z(C1-C4)Alk wherein z is 0, 1 or 2, a -NHSO2(C1-C4)Alk, -SO2NH(C1-C4)Alk, -NHSO2-(C1-C4...
|
|
WO/2003/048113A1 |
Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and&sol or monoamine activity. In formula I, R1 is selected from alkyl, aryl, alkylaryl, substitured alkyl, substituted aryl, and substitute...
|
|
WO/2003/048082A2 |
The present invention relates to novel essentially pure venlafaxine and the process of preparation thereof. The present invention also relates to novel solvate forms of venlafaxine hydrochloride and the process of preparation thereof. Fu...
|
|
WO/2003/045306A2 |
Phenoxy amine compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
WO/2003/046197A1 |
The invention relates to simple and efficient preparation of optically active 7−substituted−2−aminotetralins with industrial advantage. A process for preparation of optically active 7− substituted−2−aminotetralins or salts th...
|
|
WO/2003/042164A1 |
The invention provides novel $g(b)¿2? adrenergic receptor agonist compounds of formula (I): wherein R?1¿-R?13¿ and w have any of the values described in the specification. The invention also provides pharmaceutical compositions compri...
|
|
WO/2003/042161A1 |
The invention relates to new crystalline forms I, II and III (±)-1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohex
anol-hydrochloride of the Formula (I) and hydrates thereof. The new polymorphs are of uniform morphology and can be...
|
|
WO/2003/042150A1 |
Because of having an anti−arthritic effect, inhibiting bone fracture induced by arthritis and having a high safety, benzophenone derivatives represented by the following general formula or salts thereof are useful as remedies for arthr...
|
|
WO/2003/042160A1 |
The invention provides novel β2 adrenergic receptor agonist compounds of Formula (I). WhereinR1 is methoxy or ethoxy, and R2 is hydrogen or phenyl; or R1 is hydrogen, and R2 is phenyl; and R3 is -CH2OH or -NHCHO, and R4 is hydrogen; or ...
|
|
WO/2003/040096A2 |
Disclosed are compounds of the formula (I), wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of betasecretase and are therefore useful in treating a variety of discorder...
|
|
WO/2003/040277A2 |
Compounds of formula (I) below: wherein R?1¿ and R?2¿ can be independently a substituted or unsubstituted, saturated or unsaturated C¿1?-C¿36? hydrocarbon group, or a -RX(AO)¿n?-R?4¿ group in which R is a C¿6?-C¿10? arylene group...
|
|
WO/2003/040080A2 |
This invention is directed to lipoxin A¿4? analogs of the following formulas (I) and (II), wherein R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in ...
|
|
WO/2003/037851A1 |
Racemic tamsulosin free base is obtained in solid form. The solid form can be formed by precipitating racemic tamsulosin free base from a solvent that comprises at least one of water or a lower alcohol. The crystalline free base exhibits...
|
|
WO/2003/037850A1 |
Optically impure tamsulosin including racemic tamsulosin can be resolved into optically pure (R)- or (S)-tamsulosin by the use of diastereomeric sulfonate salts of tamsulosin in a fractional crystallization technique.
|
|
WO/2003/037831A2 |
Disclosed is a method for preparing a 4-nitroso-substituted aromatic amine that includes contacting an amide compound with a nitroaromatic compound in the presence of a base and a solvent to directly prepare 4-nitroso-substituted aromati...
|
|
WO/2003/037879A1 |
The invention relates to substituted (1H)-quinoxalin-2-one compounds, methods for production thereof, medicaments containing said compounds and the use of said compounds for the production of medicaments. The invention further relates to...
|
|
WO/2003/035599A1 |
Novel quaternary ammonium compounds of the formula (I) and any stereoisomers thereof, wherein, R1, R2, and R3 independently represent C1−C6 alkyl, optionally substituted with phenyl or hydroxyl, or both, and wherein any two of R1, R2 a...
|
|
WO/2003/035603A1 |
The invention relates to novel substituted acetic acid derivatives, to methods for their production and to their use in medicaments, in particular as potent compounds for PPAR-delta activation, for the prophylaxis and/or treatment of car...
|
|
WO/2003/035008A2 |
Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel s...
|
|
WO/2003/033467A1 |
The present invention relates to compounds of the formula (I): in which: W, R?t¿, i and R?1¿ are as defined in Claim 1, that can be used for treating pathologies characterized by an oxidative stress condition and a lack of availability...
|
|
WO/2003/031389A1 |
A compound represented by the following general formula (I) (wherein R1 represents hydrogen, hydroxy, or alkoxy; R2 represents hydroxy or optionally substituted alkoxy; R3 represents hydrogen or optionally substituted alkyl; Y represents...
|
|
WO/2003/029185A1 |
There are provided novel compounds of formula (I) wherein A, R?1¿, R?3¿, R?4¿, R?5¿, T, U, V, W, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparatio...
|
|
WO/2003/029186A1 |
Compositions comprising (±)-2-((dimethylamino)methyl)cyclohexanone, a transition-metal salt, and an organic solvent and methods ofpreparing (±)-cis-2-((dimethylamino)methyl)-l-(aryl)cyclohexanols, in particular (±)-cis-2-((dimethylami...
|
|
WO/2003/029184A1 |
A diaryl ether derivative having excellent immunosuppressive activity and reduced in side effects. The diaryl ether derivative is represented by the general formula (1): (1) &lcub e.g., 2−amino−2−[4−(3−benzyloxyphenoxy)−2−c...
|
|
WO/2003/029208A2 |
The invention relates to a method for producing vanillylamine or one of the salts thereof, whereby a) vanillin is reacted with hydroxylamine or the salts of the same in the presence of an organic salt which can optionally be produced in ...
|
|
WO/2003/029189A1 |
A process for producing a compound represented by the formula [IV] which comprises the steps (1) to (3): a step in which a compound represented by the formula [I] is reacted with either a compound represented by the formula [VI] or a mix...
|
|
WO/2003/024917A1 |
The present invention relates to novel bridged p-phenylenediamines, the use thereof as developer components in oxidation dyes as well as novel oxidation dyes, which contain the aforementioned bridged p-phenylenediamines. Said invention a...
|
|
WO/2003/024916A1 |
It is intended to provide ethyl (−)−2−[4−[2−[[(1S,2R)−2−hydroxy−2−(4−hyd
roxyphenyl)−1−methylethyl]amino]ethyl−2,5−dimethylph
enoxy]acetate hydrochloride, which has excellent effects of stimulating β3 adrenal...
|
|
WO/2003/024440A1 |
The present invention relates to novel, substituted salicylic acid salts of salmeterol as well as to methods for the production and use thereof as medicaments.
|
|
WO/2003/024439A1 |
The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of...
|
|
WO/2003/022259A1 |
The invention is directed, in part, to racemic and stereomerically pure 2-hydroxy derivatives of sibutramine and its metabolites, and 2-hydroxy derivatives of desmethylsibutramine and didesmethylsibutramine in particular. The invention i...
|
|
WO/2003/020686A2 |
The invention relates to a method for producing 4-amino-1-naphthol ethers which is characterized in that naphthol ethers are firstly produced from 1-naphthols, are subsequently transformed into corresponding 4-acetamino-1-naphthol ethers...
|
|
WO/2003/018534A1 |
The present invention relates to a new tertiary or quaternary nitrogen-containing ortho ester-based surfactant, where the hydrophobic and hydrophilic parts are attached by separate ortho ester linkages. The ortho ester surfactants are st...
|
|
WO/2003/018762A2 |
Compounds that are selective binding agents specific for RNA secondary and tertiary structures and a fluorescence assay for detecting the binding of small molecules to T-box antiterminator model mRNAs. The compounds include novel tri-sub...
|
|
WO/2003/018070A1 |
This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compound...
|
|
WO/2003/017955A1 |
The invention concerns dyeing agents for keratinous fibers based on a developer-coupler combination, characterized in that they contain at least a 3-aminophenol derivative of formula (I) or a salt thereof, water-soluble and physiological...
|
|
WO/2003/016261A1 |
The invention relates to substituted octahydrophenanthrene compounds of general formula (I), to a method for their production, to medicaments containing these compounds and to the use of said compounds for producing medicaments.
|
|
WO/2003/014060A1 |
The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.
|
|
WO/2003/014061A1 |
The invention relates to the production of amines by the reaction of aldehydes or ketones with ammonia or primary or secondary amines in the presence of a hydrogen-donor and the presence of homogeneous metal catalysts of the eighth sub-g...
|
|
WO/2003/012253A2 |
A method of reducing the aggregation and deposition of asphaltene from a fluid containing asphaltene, such as crude oil, which method comprises the addition to the fluid of a compound of formula (I): wherein A is an optionally substitute...
|
|
WO/2003/011252A1 |
The present invention provides a composition comprising (i) a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X-Y-Z- wherein X is an acetylenic hydrocarbyl group ...
|
